Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Abroad (travel likely)RecruitingPHASE1
Conditions
Neurofibroma, Plexiform · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Promyelocytic, Acute · Sarcoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (Rosandra N. Kaplan, M.D.) · NCIPOBSTReferrals@mail.nih.gov · (240) 760-6198
Study leads
Rosandra N Kaplan, M.D.
Principal Investigator
National Cancer Institute (NCI)